Volume 1.31 | Aug 20

Prostate Cell News 1.31, August 20, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


FZD4 as a Mediator of ERG Oncogene–Induced WNT Signaling and Epithelial-to-Mesenchymal Transition in Human Prostate Cancer Cells 
Here, scientists show that ERG knockdown in VCaP prostate cancer cells causes an activation of cell adhesion, resulting in strongly induced active beta1-integrin and E-cadherin expression as well as changes in WNT signaling. [Cancer Res]

Watch Procedure Now  
Detect 7x More Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies


More Prostate Cancer Diagnosed in Brothers: Study
Men with a brother who has prostate cancer are more likely than other men to be diagnosed with the disease, but screening rather than genetics may be behind it, a new study suggests. [Press release from CBC News discussing online prepublication in the Journal of the National Cancer Institute]

Prostate Cancer Death Related to BCR, but Rare Outcome
US research shows that biochemical recurrence (BCR) of prostate cancer after treatment is associated with prostate cancer mortality, although only a minority of elderly men with recurrence will die from the disease. [Press release from MedWire News discussing online prepublication in Archives of Internal Medicine]

Finasteride Use Up in VHA System but Not for Prevention
Finasteride prescriptions in the Veterans Health Administration (VHA) increased between 2000 and 2005, but the increase probably was not due to doctors prescribing it for prostate cancer chemoprevention, according to research. [Press release from Modern Medicine discussing online prepublication in Cancer Epidemiology, Biomarkers & Prevention]

Prediction of Prostate Cancer Progression Possible with Hyperspectral Imaging
A study conducted by scientists at ChemImage Corporation, in partnership with a well-known U.S. medical research and treatment center, revealed that Raman Molecular Imaging (RMI), a type of hyperspectral imaging, has great potential in predicting the progression of prostate cancer. [Press release from Chemimage Corporation discussing online prepublication in the British Journal of Urology International]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Phosphorylation and Activation of Androgen Receptor by Aurora-A
In this study, scientists demonstrate elevated levels of Aurora-A in androgen-refractory LNCaP-RF but not androgen-sensitive LNCaP cells, which prompted us to examine whether Aurora-A regulates androgen receptor and whether elevated Aurora-A is involved in androgen-independent cell growth. [J Biol Chem]

Androgen-Regulated Expression of Arginase 1, Arginase 2 and Interleukin-8 in Human Prostate Cancer 
In this report, researchers demonstrate that both arginase 1 and arginase 2 are expressed by hormone-sensitive and hormone-refractory prostate cancer cell lines, with the LNCaP cells having the highest arginase activity. [PLoS ONE]

Pharmacological Targeting of Constitutively Active Truncated Androgen Receptor by Nigericin and Suppression of Hormone-Refractory Prostate Cancer Cell Growth
Here investigators established a reporter system that monitors androgen receptor-mediated activation of a prostate specific antigen promoter. [Mol Pharmacol]

Inactivation of the WASF3 Gene in Prostate Cancer Cells Leads to Suppression of Tumorigenicity and Metastases
The WASF3 protein is involved in cell movement and invasion, and to investigate its role in prostate cancer progression scientists studied the phenotypic effects of knockdown in primary tumors and cell lines. [Br J Cancer]

Epigenetic Silencing of SOCS3 Identifies a Subset of Prostate Cancer with an Aggressive Behavior
The data suggest that suppressor of cytokine signaling 3 (SOCS3) hypermethylation may be involved in the pathogenesis of prostate cancer and could identify a tumor subset with an aggressive behavior. [Prostate]

Statins Reduce the Androgen Sensitivity and Cell Proliferation by Decreasing the Androgen Receptor Protein in Prostate Cancer Cells
In the present study, scientists determined the molecular mechanisms related to the regulation of prostate-specific antigen, androgen receptor and cell proliferation in prostate cancer cell lines by statins. [Prostate]

Type-1 Polarized Dendritic Cells Loaded with Apoptotic Prostate Cancer Cells are Potent Inducers of CD8+ T Cells Against Prostate Cancer Cells and Defined Prostate Cancer-Specific Epitopes
In order to develop improved vaccines for patients with recurrent prostate cancer (PCa), investigators tested the feasibility of using type-1 polarized dendritic cells to cross-present antigens from allogeneic PCa cells and to induce functional CD8+ T cell responses against PCa cells and against defined MHC class I-restricted PCa-relevant epitopes. [Prostate]


Effects of Prostate-Specific Antigen Testing on Familial Prostate Cancer Risk Estimates
The aim of this study was to investigate whether increased diagnostic activity is related to the incidence of prostate cancer among brothers of men with prostate cancer. [J Natl Cancer Inst]

Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans
To describe patterns of biochemical recurrence and subsequent mortality, researchers conducted an observational study in a community-based, “high-comorbidity” setting of 623 US veterans diagnosed as having prostate cancer from 1991 to 1995 and receiving radical prostatectomy or radiation therapy. [Arch Intern Med]

Knowledge and Use of Finasteride for the Prevention of Prostate Cancer

Investigators examined the influence of the Prostate Cancer Prevention Trial on finasteride prescribing within the Veterans Health Administration. [Cancer Epidemiol Biomarkers Prev]

Raman Spectral Imaging of Prostate Cancer: Can Raman Molecular Imaging be Used to Augment Standard Histopathology?
The purpose of the study is to evaluate whether Raman molecular imaging (which combines digital imaging and analytical spectroscopy to evaluate the biochemical composition of interrogated material) can be used to identify biochemical differences in patients with Gleason 7 prostate cancer who progress to metastatic disease and die from prostate cancer. [BJU Int]

Metronomic Administration of Zoledronic Acid and Taxotere Combination in Castration Resistant Prostate Cancer Patients. Phase I ZANTE Trial
Twenty-two patients enrolled into the study (median age: 73 years; range: 43-80) received one of three escalated doses of docetaxel (DTX) [30, 40 and 50mg/m(2)] in combination with a fixed dose of zoledronic acid (ZOL) (2mg), both administered every 14 days in two different sequences: DTX at the day 1 followed by ZOL at the day 2 (sequence A) or the reverse (sequence B). Patients were evaluated for adverse events and serum IL-8, MMP-2 and MMP-9 were evaluated prior and after therapy with the two sequences of administration of DTX and ZOL. [Cancer Biol Ther]

Incidence of Insignificant Prostate Cancer Using Free/Total PSA: Results of a Case-Finding Protocol on 14453 Patients
The aim of this study is to evaluate prostate cancer (PCa) detection and incidence of pathologically insignificant PCa (pIPCa) tumour using percent-free PSA (%f-PSA) in patients with total PSA less than or equal to 10 ng/ml. [Prostate Cancer Prostatic Dis]


CRT and ValiRx Sign Licensing Deal to Develop Prostate Cancer Treatment
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer. [Cancer Research Technology Press Release]

Calypso Medical Signs European Product Distribution Agreement with Siemens Heathcare
Calypso Medical Technologies, Inc. announced that it has entered into a non-exclusive product distribution agreement with Siemens Healthcare for the sale of its Calypso® System in Europe. [Calypso Medical Technologies, Inc. Press Release]

Ariadne, Cellecta and Roswell Park Cancer Institute to Collaborate on Prostate-Specific Pathway Models
Ariadne Genomics announces a joint collaboration with Cellecta and Roswell Park Cancer Institute to develop a comprehensive knowledgebase of prostate-specific pathway models. [Ariadne Genomics Press Release]

Emerson Ecologics Exclusively Offers EcoNugenics ProstaCaid
Emerson Ecologics, LLC announces the exclusive distribution of EcoNugenics’ newest product ProstaCaid™ to healthcare practitioners. [Emerson Ecologics, LLC Press Release]

Otago Prostate Cancer Research Receives Men’s Health Trust Funding
Research at Otago University to develop a better screening test for the early detection of prostate cancer has been advanced due to a $30,000 grant from the Men’s Health Trust New Zealand. [University of Otago Press Release]


Human Genetics Commission Sets New Standards for Direct-to-Consumer Genetic Tests
The Common Framework of Principles for direct-to-consumer genetic testing services, published by the Human Genetics Commission, aims to ensure that people who choose to buy genetic tests themselves can have confidence that the companies selling them follow basic principles of consent, data protection, truth in marketing, scientific rigor and balanced interpretation. [Human Genetics Commission, United Kingdom]

EU Agency Allows Access to Drug Side Effects Data
The European Medicines Agency has agreed to provide access to studies about drug side effects, following criticism over data secrecy from the European Ombudsman. [European Medicines Agency, European Union]

University of California, Berkeley Alters DNA Testing Program
The California Department of Public Health has instructed the University of California, Berkeley, not to proceed with a portion of its ground-breaking program to educate students about genetic testing and personalized medicine. [California Department of Public Health, United States]

Comprehensive List of Guidance Documents at the Food and Drug Administration [Docket No. FDA-1998-N-0050] (formerly Docket No. 1998N-0046) [Food and Drug Administration, United States]

Proposed Collection; Comment Request; NIH NCI Central Institutional Review Board (CIRB) Initiative (NCI) (FR Doc. 2010-20167) [National Institutes of Health, United States]

National Human Genome Research Institute; Notice of Closed Meeting (FR Doc. 2010-19939) [National Institutes of Health, United States]

7342.007 Addendum – Imported Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) [Center for Biologics Evaluation and Research, United States]

EVENTS (Listed by Date)

Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
August 23-27, 2010
Toronto, Canada

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 2nd Annual World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

The Science of Global Prostate Cancer Disparities in Black Men
August 27-29, 2010
Jacksonville, United States

28th World Congress of Endourology and SWL
September 1-4, 2010
Chicago, United States

Prostate Cancer Research Institute Conference 2010
September 11-12, 2010
Los Angeles, United States

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Tissue Engineering and Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010
September 15-17, 2010
Sydney, Australia

2010 Prostate Cancer Canada (PCCN) Conference
September 22-25, 2010
Toronto, Canada

International Society for Cellular Therapy 2nd Annual Symposium on Stem Cell Translation: Best Practices & Regulatory Considerations
September 27-28, 2010
San Francisco, United States

35th European Society for Medical Oncology (ESMO) Congress
October 8–12, 2010
Milan, Italy

Frontiers in Tumour Progression
October 24-27, 2010
Madrid, Spain

Cancer Pharmacogenetics: Personalising Medicine
November 22-24, 2010
Madrid, Spain

NEW IMPaCT: Innovative Minds in Prostate Cancer Today 2011
March 9-12, 2011
Orlando, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Cell Therapy Technologist (Opexa Therapeutics)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us